BOS
PTGX icon

Bingham Osborn & Scarborough’s Protagonist Therapeutics PTGX Stock Holding History

Bingham Osborn & Scarborough’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,640
Closed -$206K – 107
2021
Q3 		$206K Hold
11,640
– – 0.01% 154
2021
Q2 		$522K Sell
11,640
-4,000
-26% -$132K 0.04% 84
2021
Q1 		$405K Sell
15,640
-10,000
-39% -$253K 0.03% 96
2020
Q4 		$517K Buy
+25,640
New +$552K 0.04% 68

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bingham Osborn & Scarborough's PTGX Position: Q4 2021 in Review

Bingham Osborn & Scarborough sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 11,640 shares — an estimated $206K sold.

Bingham Osborn & Scarborough first reported a position in PTGX in Q4 2020 and held it in 4 quarters. The position peaked at $522K in Q2 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

  • Bingham Osborn & Scarborough reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 11,640 Protagonist Therapeutics shares in Q4 2021, an estimated $206K.
  • Bingham Osborn & Scarborough first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 4 quarters.
  • Bingham Osborn & Scarborough's Protagonist Therapeutics position peaked at $522K in Q2 2021.
  • 149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2021.